| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development costs | 50,696 | |||
| General and administrative costs | 1,750,658 | |||
| Total costs and expenses | 1,801,354 | |||
| Loss from operations | -1,801,354 | |||
| Interest income | 4,430 | |||
| Interest expense | 457 | |||
| Unrealized gain (loss) on digital assets | -182,887 | |||
| Realized gain (loss) on foreign currency transactions | -130 | |||
| Net loss | -1,980,398 | |||
| Series b convertible preferred stock 8 cumulative dividend | -50,367 | |||
| Net loss attributable to common stockholders | -2,030,765 | |||
| Net loss per common share basic | -0.33 | |||
| Net loss per common share diluted | -0.33 | |||
| Weighted average common shares outstanding basic | 6,171,195 | |||
| Weighted average common shares outstanding diluted | 6,171,195 | |||
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)